The approval of orforglipron signals both a shift toward more accessible obesity treatments and a test case for the FDAs new accelerated review pathway
(verified owner) Verified review - view original Always fast and easy Rated 5 out of 5 Cheryl B
Wang Y, Li G, Goode J, Paz JC, Ouyang K, Screaton R, et al
Goal: To maintain patient safety, ensure market transparency, and uphold regulatory compliance even after discontinuation
New or worsening suicidal thoughts or behaviors Signs of liver damage, like stomach pain, dark urine, or yellow eyes/skin Manic episodes (unusually high energy, reckless behavior, fast thoughts) Vision problems or eye pain/redness, possible narrow-angle glaucoma Severe allergic reactions such as rash, swelling, or trouble breathing Opioid use complications: if you require opioids, stop Contrave before use